Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Q Wu

Showing results (21-30 of 201) with videos related to

Pageof 21
Sort By:
Current Medical Research and Opinion|June 19, 2015
Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review studyAki Shiozawa, Martin Cloutier, Julie Heroux, et al.
Journal of Occupational and Environmental Medicine|May 14, 2005
Employees with overactive bladder: work loss burdenEric Q Wu, Howard Birnbaum, Maryna Marynchenko, et al.
Value in Health Regional Issues|October 22, 2019
The Development of Health Technology Assessment in Asia: Current Status and Future TrendsGordon Liu, Eric Q Wu, Jeonghoon Ahn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatmentRajeev Ayyagari, Wenhui Wei, David Cheng, et al.
Journal of Medical Economics|November 17, 2012
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United StatesJipan Xie, Melissa Diener, Gourab De, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 31, 2018
Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class AnalysisRuixuan Jiang, Ernest Law, Zhou Zhou, et al.
Journal of Medical Economics|July 7, 2011
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancerHongbo Yang, Andrew P Yu, Eric Q Wu, et al.
Advances in Therapy|June 7, 2019
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature ReviewYifei Liu, Min Yang, Vishvas Garg, et al.
Journal of Medical Economics|November 26, 2014
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapyAnnie Guerin, Medha Sasane, Genevieve Gauthier, et al.
Journal of Occupational and Environmental Medicine|August 12, 2006
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured populationG Colice, Eric Q Wu, H Birnbaum, et al.
Pageof 21

Showing results (21-30 of 201) with videos related to

Sort By:
Pageof 21
Current Medical Research and Opinion|June 19, 2015
Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review studyAki Shiozawa, Martin Cloutier, Julie Heroux, et al.
Journal of Occupational and Environmental Medicine|May 14, 2005
Employees with overactive bladder: work loss burdenEric Q Wu, Howard Birnbaum, Maryna Marynchenko, et al.
Value in Health Regional Issues|October 22, 2019
The Development of Health Technology Assessment in Asia: Current Status and Future TrendsGordon Liu, Eric Q Wu, Jeonghoon Ahn, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 17, 2015
Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatmentRajeev Ayyagari, Wenhui Wei, David Cheng, et al.
Journal of Medical Economics|November 17, 2012
Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United StatesJipan Xie, Melissa Diener, Gourab De, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 31, 2018
Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class AnalysisRuixuan Jiang, Ernest Law, Zhou Zhou, et al.
Journal of Medical Economics|July 7, 2011
Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancerHongbo Yang, Andrew P Yu, Eric Q Wu, et al.
Advances in Therapy|June 7, 2019
Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature ReviewYifei Liu, Min Yang, Vishvas Garg, et al.
Journal of Medical Economics|November 26, 2014
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapyAnnie Guerin, Medha Sasane, Genevieve Gauthier, et al.
Journal of Occupational and Environmental Medicine|August 12, 2006
Healthcare and workloss costs associated with patients with persistent asthma in a privately insured populationG Colice, Eric Q Wu, H Birnbaum, et al.
Pageof 21